- |||||||||| Trial initiation date: Tissue Sodium in Autoimmune Disease (clinicaltrials.gov) - May 10, 2017
P=N/A, N=21, Not yet recruiting, N=1000 --> 0 | Not yet recruiting --> Withdrawn Initiation date: Apr 2017 --> Dec 2017
- |||||||||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion, Trial primary completion date: Protection Against Pneumococcal Infection in Children With T1DM (clinicaltrials.gov) - May 9, 2017 P4, N=50, Completed, Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Apr 2016
- |||||||||| Trial completion, Phase classification, Trial primary completion date: Low Level Laser Therapy for Autoimmune Thyroiditis (clinicaltrials.gov) - May 5, 2017
P=N/A, N=43, Completed, Trial primary completion date: Jun 2014 --> Mar 2014 Active, not recruiting --> Completed | Phase classification: P2/3 --> PN/A | Trial primary completion date: Nov 2015 --> Mar 2016
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Physical Telerehabilitation in Veterans With Multiple Sclerosis (clinicaltrials.gov) - May 5, 2017
P=N/A, N=74, Completed, Active, not recruiting --> Completed | Phase classification: P2/3 --> PN/A | Trial primary completion date: Nov 2015 --> Mar 2016 Recruiting --> Completed | N=170 --> 74 | Trial primary completion date: Jul 2015 --> Apr 2017
- |||||||||| Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest
Trial completion: Immunogenicity of HPV Vaccine in Immunosuppressed Children (clinicaltrials.gov) - May 4, 2017 P3, N=55, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Enrollment closed, Enrollment change: PBR28 PET and Inflammatory Arthritis (clinicaltrials.gov) - May 4, 2017
P=N/A, N=22, Active, not recruiting, N=13 --> 20 | Trial primary completion date: Jan 2017 --> Jan 2018 Recruiting --> Active, not recruiting | N=12 --> 22
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
New trial, Checkpoint inhibition, Metastases: CHECKAUTO: Immune Checkpoint Inhibitors and Pre-existing Autoimmune Diseases (clinicaltrials.gov) - May 4, 2017 P=N/A, N=50, Recruiting,
- |||||||||| Trial completion, Enrollment change: The ANCA Vasculitis Questionnaire (AAV-PRO (clinicaltrials.gov) - May 3, 2017
P=N/A, N=280, Completed, Initiation date: Feb 2017 --> Sep 2017 Active, not recruiting --> Completed | N=500 --> 280
- |||||||||| rivaroxaban / Generic mfg., warfarin / Generic mfg.
Trial primary completion date: TRAPS: Rivaroxaban in Thrombotic Antiphospholipid Syndrome (clinicaltrials.gov) - May 3, 2017 P3, N=536, Recruiting, Active, not recruiting --> Completed | N=500 --> 280 Trial primary completion date: Dec 2018 --> Dec 2020
- |||||||||| prednisone delayed-release tablet / Generic mfg.
Phase classification, Enrollment change, Trial termination: Delayed Release Prednisone in PMR (clinicaltrials.gov) - May 3, 2017 P2, N=8, Terminated, Active, not recruiting --> Completed | Phase classification: P2 --> P1/2 | N=84 --> 64 Phase classification: P4 --> P2 | N=45 --> 8 | Recruiting --> Terminated; lack of study recruitment
- |||||||||| Trial completion, Phase classification, Trial primary completion date: Walk for Rheumatoid Arthritis (WARA Study) (clinicaltrials.gov) - May 3, 2017
P=N/A, N=76, Completed, Phase classification: P4 --> P2 | N=45 --> 8 | Recruiting --> Terminated; lack of study recruitment Recruiting --> Completed | Phase classification: P1/2 --> PN/A | Trial primary completion date: Dec 2015 --> Mar 2016
- |||||||||| Trial primary completion date: Brown Adipose Tissue in Type 1 Diabetes (clinicaltrials.gov) - May 3, 2017
P=N/A, N=12, Recruiting, Recruiting --> Completed | Phase classification: P1/2 --> PN/A | Trial primary completion date: Dec 2015 --> Mar 2016 Trial primary completion date: Mar 2017 --> Sep 2017
- |||||||||| staphylococcal protein A (PRTX-100) / Protalex
Phase classification, Trial primary completion date: PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP (clinicaltrials.gov) - Apr 28, 2017 P1b, N=30, Recruiting, Trial primary completion date: Feb 2017 --> Feb 2018 Phase classification: P1/2 --> P1b | Trial primary completion date: Jun 2017 --> Dec 2017
- |||||||||| Orencia (abatacept) / BMS
Trial primary completion date: Safety Study of Abatacept to Treat Rheumatoid Arthritis (B) (clinicaltrials.gov) - Apr 27, 2017 P=N/A, N=20000, Active, not recruiting, Phase classification: P1/2 --> P1b | Trial primary completion date: Jun 2017 --> Dec 2017 Trial primary completion date: Mar 2017 --> Aug 2017
- |||||||||| Phase classification: Project JAY THA Registration Study (clinicaltrials.gov) - Apr 27, 2017
P=N/A, N=100, Completed, Active, not recruiting --> Completed Phase classification: P3 --> P=N/A
- |||||||||| azithromycin / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date, Immunomodulating: Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy (clinicaltrials.gov) - Apr 27, 2017 P1/2, N=0, Withdrawn, Active, not recruiting --> Completed | Trial primary completion date: Dec 2018 --> Mar 2017 N=14 --> 0 | Enrolling by invitation --> Withdrawn | Trial primary completion date: Jul 2012 --> Nov 2014
|